乳癌治疗市场 - 依治疗方式（标靶治疗、荷尔蒙治疗、化疗、免疫治疗），全球预测，2023-2032 年

Breast Cancer Therapeutics Market - By Therapy (Targeted Therapy, Hormonal Therapy, Chemotherapy, Immunotherapy), Global Forecast, 2023-2032

出版日期: 2023年11月01日 | 出版商:

Global Market Insights Inc. | 英文 90 Pages | 商品交期: 2-3个工作天内

价格

简介目录图表

在乳癌领域的新事件和强劲的研究与开发的推动下，2023 年至 2032 年间，全球乳癌治疗市场的CAGR将达到 7.3%。新兴研究揭示了创新疗法，推动了对先进治疗方案的需求。

例如，2023 年 12 月，在 2023 年圣安东尼奥乳癌研讨会 (SABCS) 上，研究重点关注了可改善转移性乳癌患者预后的研究性治疗方法，并深入了解治疗抗药性。其中一项研究HER2CLIMB-02 试验表明，将图卡替尼纳入曲妥珠单抗emtansine (T-DM1) 治疗中可以延长既往接受过治疗的HER2 阳性转移性或局部晚期乳腺癌患者的无进展生存期(PFS)。精准医学、免疫疗法和标靶疗法的突破促进了市场成长，满足了对更有效和个人化乳癌治疗不断增长的需求。随着科学发现和事件不断发展的动态格局，市场响应了对乳癌治疗改善结果和增强疗法的持续追求

乳癌治疗市场的总体份额根据治疗和地区进行分类。

2023年至2032年，化疗领域的市场规模将出现显着的CAGR。儘管标靶治疗取得了进步，但化疗仍然具有重要意义，特别是在侵袭性癌症类型中。它在新辅助和辅助治疗中的作用以及新兴的联合疗法维持了需求。透过不断改进以尽量减少副作用并提高疗效，化疗保持关键地位，满足不同患者的需求。它在乳癌治疗中的持久作用继续刺激治疗市场的需求，确保为患者提供全面的护理和治疗选择。

亚太地区乳癌治疗产业从 2023 年到 2032 年将呈现出值得称讚的CAGR。发病率不断上升，并且对医疗保健基础设施的日益关注。随着亚太地区乳癌发生率激增，人们越来越重视创新疗法和先进的治疗选择。随着医疗保健系统的不断发展和向个人化医疗的转变，对标靶治疗和尖端治疗的需求不断增加。这个蓬勃发展的市场迎合了该地区对改善结果的追求，在亚太地区的医疗保健领域培育了乳癌治疗的动态格局。

例如，2023 年 12 月，辉瑞、莫纳什大学和澳洲癌症治疗合作研究中心合作发现了一种治疗雌激素受体 (ER) 阳性乳癌的潜在临床前药物。这项研究揭示了 CTx-648，一种口服生物可利用的「KAT6A/B」抑制剂，显示出卓越的选择性和效力。在小鼠模型中，CTx-648 在 ER 阳性乳癌中表现出显着的抗肿瘤作用，即使在对荷尔蒙治疗抗药性的情况下也是如此。这项突破为针对 KAT6A 治疗 ER 阳性乳癌带来了新的前景，可能为患者提供新的治疗途径。

产业格局
产业影响力
- 成长动力
  - 乳癌负担日益加重
  - 加大研发投入
  - 启动多项诊断和筛检计划
  - 优惠的保险和报销政策
- 产业陷阱与挑战
  - 与乳癌药物相关的副作用
  - 药品费用高
- 成长潜力分析
- 透过治疗
COVID-19 影响分析
监管环境
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：乳癌治疗市场估计与预测：按治疗方法，2018-2032 年

主要动力向：透过治疗
标靶治疗
荷尔蒙疗法
化疗
免疫疗法

第 6 章：乳癌治疗市场估计与预测：按地区，2018 - 2032

主要动向：按地区
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 中东和非洲其他地区

第 7 章：公司简介

AstraZeneca plc.
Eli Lilly & Co, Inc.
Pfizer, Inc.
Novartis AG
Amgen
F. Hoffmann La Roche AG
Merck & Co, Inc.
Gilead Sciences, Inc.
Eisai Co., Ltd.
Macrogenics, Inc.
Stemline Therapeutics, Inc.

简介目录图表

Product Code: 466

Global Breast Cancer Therapeutics Market will witness 7.3% CAGR between 2023 and 2032 propelled by novel events and robust research and development within the breast cancer domain. Emerging studies uncover innovative therapies, driving demand for advanced treatment options.

For instance, in December 2023, at the 2023 San Antonio Breast Cancer Symposium (SABCS), research spotlighted investigational treatments offering improved outcomes for metastatic breast cancer patients and insights into treatment resistance. One such research, The HER2CLIMB-02 trial revealed that incorporating tucatinib into trastuzumab emtansine (T-DM1) therapy extended progression-free survival (PFS) among individuals with previously treated HER2-positive metastatic or locally advanced breast cancer. Breakthroughs in precision medicine, immunotherapy, and targeted therapies amplify market growth, meeting the escalating need for more effective and personalized breast cancer treatments. With a dynamic landscape of scientific discoveries and evolving events, the market responds to the continuous quest for improved outcomes and enhanced therapies in the fight against breast cancer

The overall Breast Cancer Therapeutics Market share is classified based on therapy, and region.

The market size from the chemotherapy segment will register a noteworthy CAGR from 2023 to 2032. Despite advancements in targeted therapies, chemotherapy retains its significance, especially in aggressive cancer types. Its role in neoadjuvant and adjuvant settings, alongside emerging combination therapies, sustains demand. With ongoing refinements to minimize side effects and enhance efficacy, chemotherapy maintains a pivotal stance, meeting the needs of diverse patient profiles. Its enduring role in breast cancer treatment continues to fuel demand within the therapeutics market, ensuring comprehensive care and treatment options for patients.

Asia Pacific breast cancer therapeutics industry will showcase a commendable CAGR from 2023 to 2032. rising incidences and a growing focus on healthcare infrastructure. As breast cancer rates surge across Asia Pacific, there's an increased emphasis on innovative therapies and advanced treatment options. With evolving healthcare systems and a shift toward personalized medicine, the demand for targeted therapies and cutting-edge treatments rises. This burgeoning market caters to the region's quest for improved outcomes, fostering a dynamic landscape of breast cancer therapeutics within Asia Pacific's healthcare domain.

For instance, in December 2023, A collaborative effort between Pfizer, Monash University, and the Cancer Therapeutics Cooperative Research Centre, in Australia uncovered a potential pre-clinical drug for Estrogen Receptor (ER) positive breast cancer. This study unveiled CTx-648, an orally bioavailable 'KAT6A/B' inhibitor showing remarkable selectivity and potency. In mouse models, CTx-648 demonstrated significant anti-tumor effects in ER-positive breast cancer, even in cases resistant to hormone therapy. This breakthrough introduces a new prospect for targeting KAT6A in ER-positive breast cancer, potentially offering a novel treatment avenue for patients.

Chapter 1 Methodology & Scope

1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast Calculation
1.4 Covid-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Breast cancer therapeutics industry 360 degree synopsis, 2018 - 2032 (USD Million)
- 2.1.1 Business trends
- 2.1.2 Regional trends
- 2.1.3 Therapy trends

Chapter 3 Breast Cancer Therapeutics Market Insights

3.1 Industry landscape, 2018 - 2032 (USD Million)
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing burden of breast cancer
  - 3.2.1.2 Increasing investments in R&D
  - 3.2.1.3 Launch of several diagnostic and screening programs
  - 3.2.1.4 Favorable insurance and reimbursement policies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Adverse-effects associated with breast cancer drugs
  - 3.2.2.2 High cost of drugs
- 3.2.3 Growth potential analysis
- 3.2.4 By therapy
3.3 COVID-19 impact analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022

Chapter 5 Breast Cancer Therapeutics Market Estimates and Forecast, By Therapy, 2018-2032 (USD Million)

5.1 Key trends, by therapy
5.2 Targeted therapy
5.3 Hormonal therapy
5.4 Chemotherapy
5.5 Immunotherapy

Chapter 6 Breast Cancer Therapeutics Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)

6.1 Key trends, by region
6.2 North America
- 6.2.1 U.S.
- 6.2.2 Canada
6.3 Europe
- 6.3.1 Germany
- 6.3.2 UK
- 6.3.3 France
- 6.3.4 Spain
- 6.3.5 Italy
- 6.3.6 Rest of Europe
6.4 Asia Pacific
- 6.4.1 China
- 6.4.2 Japan
- 6.4.3 India
- 6.4.4 Australia
- 6.4.5 Rest of Asia Pacific
6.5 Latin America
- 6.5.1 Brazil
- 6.5.2 Mexico
- 6.5.3 Rest of Latin America
6.6 Middle East & Africa
- 6.6.1 South Africa
- 6.6.2 Saudi Arabia
- 6.6.3 Rest of Middle East & Africa

Chapter 7 Company Profiles

7.1 AstraZeneca plc.
7.2 Eli Lilly & Co, Inc.
7.3 Pfizer, Inc.
7.4 Novartis AG
7.5 Amgen
7.6 F. Hoffmann La Roche AG
7.7 Merck & Co, Inc.
7.8 Gilead Sciences, Inc.
7.9 Eisai Co., Ltd.
7.10 Macrogenics, Inc.
7.11 Stemline Therapeutics, Inc.

简介目录图表

Data Tables

TABLE 1 Market revenue, by therapy (2022)
TABLE 2 Market share, by region (2022)
TABLE 3 Global breast cancer therapeutics market size, by region, 2018 - 2022 (USD Million)
TABLE 4 Global breast cancer therapeutics market size, by region, 2023 - 2032 (USD Million)
TABLE 5 Global breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 6 Global breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 7 Industry impact forces
TABLE 8 Targeted therapy market size, 2018 - 2022 (USD Million)
TABLE 9 Targeted therapy market size, 2023 - 2032 (USD Million)
TABLE 10 Hormonal therapy market size, 2018 - 2022 (USD Million)
TABLE 11 Hormonal therapy market size, 2023 - 2032 (USD Million)
TABLE 12 Chemotherapy market size, 2018 - 2022 (USD Million)
TABLE 13 Chemotherapy market size, 2023 - 2032 (USD Million)
TABLE 14 Immunotherapy market size, 2018 - 2022 (USD Million)
TABLE 15 Immunotherapy market size, 2023 - 2032 (USD Million)
TABLE 16 North America breast cancer therapeutics market size, by country, 2018 - 2022 (USD Million)
TABLE 17 North America breast cancer therapeutics market size, by country, 2023 - 2032 (USD Million)
TABLE 18 North America breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 19 North America breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 20 U.S. breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 21 U.S. breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 22 Canada breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 23 Canada breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 24 Europe breast cancer therapeutics market size, by country, 2018 - 2022 (USD Million)
TABLE 25 Europe breast cancer therapeutics market size, by country, 2023 - 2032 (USD Million)
TABLE 26 Europe breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 27 Europe breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 28 Germany breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 29 Germany breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 30 UK breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 31 UK breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 32 France breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 33 France breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 34 Spain breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 35 Spain breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 36 Italy breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 37 Italy breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 38 Rest of Europe breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 39 Rest of Europe breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 40 Asia Pacific breast cancer therapeutics market size, by country, 2018 - 2022 (USD Million)
TABLE 41 Asia Pacific breast cancer therapeutics market size, by country, 2023 - 2032 (USD Million)
TABLE 42 Asia Pacific breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 43 Asia Pacific breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 44 China breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 45 China breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 46 Japan breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 47 Japan breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 48 India breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 49 India breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 50 Australia breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 51 Australia breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 52 Rest of Asia Pacific breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 53 Rest of Asia Pacific breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 54 Latin America breast cancer therapeutics market size, by country, 2018 - 2022 (USD Million)
TABLE 55 Latin America breast cancer therapeutics market size, by country, 2023 - 2032 (USD Million)
TABLE 56 Latin America breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 57 Latin America breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 58 Brazil breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 59 Brazil breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 60 Mexico breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 61 Mexico breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 62 Rest of Latin America breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 63 Rest of Latin America breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 64 Middle East & Africa breast cancer therapeutics market size, by country, 2018 - 2022 (USD Million)
TABLE 65 Middle East & Africa breast cancer therapeutics market size, by country, 2023 - 2032 (USD Million)
TABLE 66 Middle East & Africa breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 67 Middle East & Africa breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 68 South Africa breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 69 South Africa breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 70 Saudi Arabia breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 71 Saudi Arabia breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)
TABLE 72 Rest of Middle East & Africa breast cancer therapeutics market size, by therapy, 2018 - 2022 (USD Million)
TABLE 73 Rest of Middle East & Africa breast cancer therapeutics market size, by therapy, 2023 - 2032 (USD Million)